Cullinan Therapeutics, Inc. CGEM
8.89 USD -0.18 (-1.98%)
Regular-session close
8.96 +0.07 +0.79%
After hours · Nov 20, 7:38 PM ET
8.80 Day range 9.43
8.72 52-week range 22.95
- YTD
- -14.11%
- 1 year
- +1.95%
News
seekingalpha.com Cullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 Transcript Cullinan Therapeutics, Inc. ( CGEM ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical…benzinga.com Cullinan Therapeutics Partner Taiho Oncology Completes NDA Submission To FDA For Zipalertinib In Combination With Platinum-Based Chemotherapy For Treatment Of NSCLC Harboring EGFR Ex20ins Mutations Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and…
benzinga.com Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44 Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.
benzinga.com Cullinan Therapeutics Q3 EPS $(0.74) Beats $(0.84) Estimate Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.84) by 11.9 percent. This is a 3.9 percent increase over losses of…
benzinga.com Reported Sunday, Cullinan Therapeutics Reports Velinotamig Achieved Clinically Meaningful Disease Activity Improvement In 8 Of 9 Evaluable Refractory Lupus Patients, With Four Complete Renal Responses, In Data Presented At ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction…
benzinga.com BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41 BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.
benzinga.com Cullinan Therapeutics Gets FDA And Australian Therapeutic Goods Administration Clearance To Initiate Its Global Phase 1b/2a Clinical Trial In Adults With Relapsing And Refractory ITP And Warm Autoimmune Hemolytic Anemia Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHAStudy expands immunology portfolio into autoimmune…
